US20150259283A1 - Formulation for soft anticholinergic analogs - Google Patents

Formulation for soft anticholinergic analogs Download PDF

Info

Publication number
US20150259283A1
US20150259283A1 US14/285,488 US201414285488A US2015259283A1 US 20150259283 A1 US20150259283 A1 US 20150259283A1 US 201414285488 A US201414285488 A US 201414285488A US 2015259283 A1 US2015259283 A1 US 2015259283A1
Authority
US
United States
Prior art keywords
composition
methyl
cyclopentylphenylhydroxyacetoxy
pyrrolidinium bromide
rrt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/285,488
Other languages
English (en)
Inventor
John J. Koleng
David Angulo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bodor Laboratories Inc
Original Assignee
Brickell Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brickell Biotech Inc filed Critical Brickell Biotech Inc
Priority to US14/285,488 priority Critical patent/US20150259283A1/en
Assigned to BRICKELL BIOTECH, INC. reassignment BRICKELL BIOTECH, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ANGULO, DAVID
Assigned to BRICKELL BIOTECH, INC. reassignment BRICKELL BIOTECH, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KOLENG, JOHN J.
Priority to US15/125,039 priority patent/US20170020845A1/en
Priority to EP15762178.0A priority patent/EP3116498B1/en
Priority to PT15762178T priority patent/PT3116498T/pt
Priority to BR112016021011-5A priority patent/BR112016021011B1/pt
Priority to PL15762178T priority patent/PL3116498T3/pl
Priority to JP2016556899A priority patent/JP6293919B2/ja
Priority to HUE15762178A priority patent/HUE041868T2/hu
Priority to ES15762178T priority patent/ES2710292T3/es
Priority to PCT/US2015/020253 priority patent/WO2015138776A1/en
Priority to MYPI2016703307A priority patent/MY183531A/en
Priority to DK15762178.0T priority patent/DK3116498T3/da
Priority to CN201910812881.XA priority patent/CN110420167B/zh
Priority to SG11201607480SA priority patent/SG11201607480SA/en
Priority to MX2016011529A priority patent/MX369129B/es
Priority to KR1020237033837A priority patent/KR20230145522A/ko
Priority to CN201911319136.8A priority patent/CN110917124B/zh
Priority to AU2015229243A priority patent/AU2015229243B2/en
Priority to CN201580013622.0A priority patent/CN106456603B/zh
Priority to KR1020167028122A priority patent/KR102433868B1/ko
Priority to CA2941649A priority patent/CA2941649C/en
Priority to KR1020227028128A priority patent/KR102586868B1/ko
Assigned to BODOR LABORATORIES, INC. reassignment BODOR LABORATORIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRICKELL BIOTECH, INC.
Assigned to BODOR LABORATORIES, INC. reassignment BODOR LABORATORIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BODOR, NICHOLAS S
Priority to US14/805,114 priority patent/US20150320722A1/en
Publication of US20150259283A1 publication Critical patent/US20150259283A1/en
Priority to IL247571A priority patent/IL247571B/en
Priority to PH12016501732A priority patent/PH12016501732A1/en
Priority to ZA2016/07071A priority patent/ZA201607071B/en
Assigned to BODOR LABORATORIES, INC. reassignment BODOR LABORATORIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRICKELL BIOTECH, INC.
Priority to JP2017176799A priority patent/JP6461267B2/ja
Priority to JP2018062716A priority patent/JP6756763B2/ja
Priority to JP2019127508A priority patent/JP6762047B2/ja
Priority to AU2019257421A priority patent/AU2019257421B2/en
Priority to US16/683,792 priority patent/US10961191B2/en
Priority to US16/696,077 priority patent/US10947192B2/en
Priority to JP2020035073A priority patent/JP2020079321A/ja
Priority to US17/099,163 priority patent/US11034652B2/en
Priority to US17/116,501 priority patent/US11084788B2/en
Priority to US17/202,063 priority patent/US20210198195A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
US14/285,488 2014-03-13 2014-05-22 Formulation for soft anticholinergic analogs Abandoned US20150259283A1 (en)

Priority Applications (36)

Application Number Priority Date Filing Date Title
US14/285,488 US20150259283A1 (en) 2014-03-13 2014-05-22 Formulation for soft anticholinergic analogs
CN201580013622.0A CN106456603B (zh) 2014-03-13 2015-03-12 软性抗胆碱能药类似物的制剂
MX2016011529A MX369129B (es) 2014-03-13 2015-03-12 Formulacion para analogos anticolinergicos suaves.
HUE15762178A HUE041868T2 (hu) 2014-03-13 2015-03-12 Készítmény enyhe antikolinerg analógokhoz
CA2941649A CA2941649C (en) 2014-03-13 2015-03-12 Formulation for soft anticholinergic analogs
PT15762178T PT3116498T (pt) 2014-03-13 2015-03-12 Formulação para análogos anticolinérgicos suaves
BR112016021011-5A BR112016021011B1 (pt) 2014-03-13 2015-03-12 Composição de gel anidro tópica e usos de um composto
PL15762178T PL3116498T3 (pl) 2014-03-13 2015-03-12 Preparat miękkich analogów przeciwcholinergicznych
JP2016556899A JP6293919B2 (ja) 2014-03-13 2015-03-12 ソフト型抗コリン作動薬類似体についての製剤
KR1020167028122A KR102433868B1 (ko) 2014-03-13 2015-03-12 연성 항콜린성 유사체를 위한 제제
ES15762178T ES2710292T3 (es) 2014-03-13 2015-03-12 Formulación para análogos anticolinérgicos suaves
PCT/US2015/020253 WO2015138776A1 (en) 2014-03-13 2015-03-12 Formulation for soft anticholinergic analogs
MYPI2016703307A MY183531A (en) 2014-03-13 2015-03-12 Formulation for soft anticholinergic analogs
DK15762178.0T DK3116498T3 (da) 2014-03-13 2015-03-12 Formulering til bløde anticholinerge analoger
CN201910812881.XA CN110420167B (zh) 2014-03-13 2015-03-12 软性抗胆碱能药类似物的制剂
SG11201607480SA SG11201607480SA (en) 2014-03-13 2015-03-12 Formulation for soft anticholinergic analogs
EP15762178.0A EP3116498B1 (en) 2014-03-13 2015-03-12 Formulation for soft anticholinergic analogs
KR1020237033837A KR20230145522A (ko) 2014-03-13 2015-03-12 연성 항콜린성 유사체를 위한 제제
CN201911319136.8A CN110917124B (zh) 2014-03-13 2015-03-12 软性抗胆碱能药类似物的制剂
AU2015229243A AU2015229243B2 (en) 2014-03-13 2015-03-12 Formulation for soft anticholinergic analogs
KR1020227028128A KR102586868B1 (ko) 2014-03-13 2015-03-12 연성 항콜린성 유사체를 위한 제제
US15/125,039 US20170020845A1 (en) 2014-03-13 2015-03-12 Formulation for soft anticholinergic analogs
US14/805,114 US20150320722A1 (en) 2014-03-13 2015-07-21 Formulation for soft anticholinergic analogs
IL247571A IL247571B (en) 2014-03-13 2016-08-31 Composition for soft anticholinergic analogs
PH12016501732A PH12016501732A1 (en) 2014-03-13 2016-09-02 Formulation for soft anticholinergic analogs
ZA2016/07071A ZA201607071B (en) 2014-03-13 2016-10-13 Formulation for soft anticholinergic analogs
JP2017176799A JP6461267B2 (ja) 2014-03-13 2017-09-14 ソフト型抗コリン作動薬類似体についての製剤
JP2018062716A JP6756763B2 (ja) 2014-03-13 2018-03-28 ソフト型抗コリン作動薬類似体についての製剤
JP2019127508A JP6762047B2 (ja) 2014-03-13 2019-07-09 ソフト型抗コリン作動薬類似体についての製剤
AU2019257421A AU2019257421B2 (en) 2014-03-13 2019-10-30 Formulation for soft anticholinergic analogs
US16/683,792 US10961191B2 (en) 2014-03-13 2019-11-14 Formulation for soft anticholinergic analogs
US16/696,077 US10947192B2 (en) 2014-03-13 2019-11-26 Formulation for soft anticholinergic analogs
JP2020035073A JP2020079321A (ja) 2014-03-13 2020-03-02 ソフト型抗コリン作動薬類似体についての製剤
US17/099,163 US11034652B2 (en) 2014-03-13 2020-11-16 Formulation for soft anticholinergic analogs
US17/116,501 US11084788B2 (en) 2014-03-13 2020-12-09 Formulation for soft anticholinergic analogs
US17/202,063 US20210198195A1 (en) 2014-03-13 2021-03-15 Formulation for soft anticholinergic analogs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461952505P 2014-03-13 2014-03-13
US14/285,488 US20150259283A1 (en) 2014-03-13 2014-05-22 Formulation for soft anticholinergic analogs

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US16/683,792 Continuation US10961191B2 (en) 2014-03-13 2019-11-14 Formulation for soft anticholinergic analogs

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US15/125,039 Continuation-In-Part US20170020845A1 (en) 2014-03-13 2015-03-12 Formulation for soft anticholinergic analogs
PCT/US2015/020253 Continuation-In-Part WO2015138776A1 (en) 2014-03-13 2015-03-12 Formulation for soft anticholinergic analogs
US14/805,114 Continuation-In-Part US20150320722A1 (en) 2014-03-13 2015-07-21 Formulation for soft anticholinergic analogs

Publications (1)

Publication Number Publication Date
US20150259283A1 true US20150259283A1 (en) 2015-09-17

Family

ID=54068191

Family Applications (8)

Application Number Title Priority Date Filing Date
US14/285,488 Abandoned US20150259283A1 (en) 2014-03-13 2014-05-22 Formulation for soft anticholinergic analogs
US15/125,039 Abandoned US20170020845A1 (en) 2014-03-13 2015-03-12 Formulation for soft anticholinergic analogs
US14/805,114 Abandoned US20150320722A1 (en) 2014-03-13 2015-07-21 Formulation for soft anticholinergic analogs
US16/683,792 Active US10961191B2 (en) 2014-03-13 2019-11-14 Formulation for soft anticholinergic analogs
US16/696,077 Active US10947192B2 (en) 2014-03-13 2019-11-26 Formulation for soft anticholinergic analogs
US17/099,163 Active US11034652B2 (en) 2014-03-13 2020-11-16 Formulation for soft anticholinergic analogs
US17/116,501 Active US11084788B2 (en) 2014-03-13 2020-12-09 Formulation for soft anticholinergic analogs
US17/202,063 Pending US20210198195A1 (en) 2014-03-13 2021-03-15 Formulation for soft anticholinergic analogs

Family Applications After (7)

Application Number Title Priority Date Filing Date
US15/125,039 Abandoned US20170020845A1 (en) 2014-03-13 2015-03-12 Formulation for soft anticholinergic analogs
US14/805,114 Abandoned US20150320722A1 (en) 2014-03-13 2015-07-21 Formulation for soft anticholinergic analogs
US16/683,792 Active US10961191B2 (en) 2014-03-13 2019-11-14 Formulation for soft anticholinergic analogs
US16/696,077 Active US10947192B2 (en) 2014-03-13 2019-11-26 Formulation for soft anticholinergic analogs
US17/099,163 Active US11034652B2 (en) 2014-03-13 2020-11-16 Formulation for soft anticholinergic analogs
US17/116,501 Active US11084788B2 (en) 2014-03-13 2020-12-09 Formulation for soft anticholinergic analogs
US17/202,063 Pending US20210198195A1 (en) 2014-03-13 2021-03-15 Formulation for soft anticholinergic analogs

Country Status (20)

Country Link
US (8) US20150259283A1 (da)
EP (1) EP3116498B1 (da)
JP (5) JP6293919B2 (da)
KR (3) KR102586868B1 (da)
CN (3) CN110917124B (da)
AU (2) AU2015229243B2 (da)
BR (1) BR112016021011B1 (da)
CA (1) CA2941649C (da)
DK (2) DK3116498T3 (da)
ES (1) ES2710292T3 (da)
HU (1) HUE041868T2 (da)
IL (1) IL247571B (da)
MX (1) MX369129B (da)
MY (1) MY183531A (da)
PH (1) PH12016501732A1 (da)
PL (1) PL3116498T3 (da)
PT (2) PT3116498T (da)
SG (1) SG11201607480SA (da)
WO (1) WO2015138776A1 (da)
ZA (1) ZA201607071B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008531732A (ja) * 2005-03-03 2008-08-14 ルバンス セラピュティックス インク． ボツリヌス毒素の局所塗布及び経皮送達のための組成物及び方法
CA2920110C (en) 2013-08-08 2022-05-31 Novan, Inc. Compositions and kits including a nitric oxide releasing compound and a hydrogel
US20150259283A1 (en) 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
CN108137612A (zh) 2015-07-21 2018-06-08 博多尔实验仪器公司 软性抗胆碱能药类似物的制剂
TWI719046B (zh) * 2016-07-21 2021-02-21 美商波德實驗股份有限公司 軟性抗膽鹼類似物之製劑
US11381304B2 (en) * 2017-08-30 2022-07-05 Iridium Satellite Llc Satellite communications with multiple classes of terrestrial terminal devices
KR20220011671A (ko) * 2019-05-23 2022-01-28 가켄 세이야쿠 가부시키가이샤 소프피로늄 브롬화물 결정체 및 그의 제조방법
CA3174550A1 (en) 2020-03-03 2021-09-10 Kaken Pharmaceutical Co., Ltd. Medicament containing sofpironium bromide
TW202146010A (zh) 2020-03-03 2021-12-16 日商科研製藥股份有限公司 原發性腋窩多汗症的治療方法及其醫藥
KR102655121B1 (ko) 2021-09-17 2024-04-08 한국식품연구원 락토바실러스 사케이 k040706 균주 검출용 프라이머 세트 및 이의 용도
US11807604B1 (en) * 2022-02-16 2023-11-07 Miralogx Llc Pharmaceutical compounds, pharmaceutical compositions, and methods of treating asthma and other disorders
WO2024026412A1 (en) * 2022-07-28 2024-02-01 Tff Pharmaceuticals, Inc. Thin film freezing methods and compositions formulated from dispersed active agents
KR102611847B1 (ko) * 2023-03-27 2023-12-12 주식회사 이플라스크 무스카린 수용체 길항 활성을 갖는 신규한 피롤리디늄 화합물 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030064040A1 (en) * 2001-09-26 2003-04-03 Lukacsko Alison B. Compositions and methods for inhibiting eccrine perspiration in humans

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK149832C (da) * 1981-07-17 1987-05-18 Riemann Claus Antiperspirantpraeparat bestaaende af to komponenter
CA2014633C (en) * 1989-06-02 2000-07-18 Andrew D. Mccrea Stable anhydrous compositions for topical delivery of active materials
US5292530A (en) * 1991-06-02 1994-03-08 Helene Curtis, Inc. Stable anhydrous topically-active composition and suspending agent therefor
US5232689A (en) * 1990-12-21 1993-08-03 Dow Corning Corporation Translucent antiperspirant compositions
US5895644A (en) * 1997-11-20 1999-04-20 Colgate-Palmolive Company Clear antiperspirant stick with dibenzylidene sorbitol and guar and process of making same
US6433003B1 (en) 1999-04-23 2002-08-13 Arthur M. Bobrove Method for treating hyperhidrosis in mammals
US8252316B2 (en) * 2002-05-03 2012-08-28 Purepharm Inc. Method of topically applying glycopyrrolate solution using absorbent pad to reduce sweating
US7087560B2 (en) * 2004-10-25 2006-08-08 Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. Personal care composition with salts of dihydroxypropyltri(C1-C3 alkyl) ammonium monosubstituted polyols
US20060088496A1 (en) * 2004-10-25 2006-04-27 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Personal care compositions with salts of hydroxypropyl trialkylammonium substituted mono-saccharide
GB0428416D0 (en) * 2004-12-24 2005-02-02 Novartis Ag Organic compounds
GB0428418D0 (en) * 2004-12-24 2005-02-02 Novartis Ag Organic compounds
BRPI0519481A2 (pt) * 2004-12-27 2009-02-03 Beiersdorf Ag glicopirrolato em preparaÇÕes cosmÉticas
EP1951186A4 (en) * 2005-10-19 2009-11-04 Menni Menashe Zinger METHODS FOR TREATING HYPERHIDROSIS
AU2006315657B2 (en) * 2005-11-10 2011-12-01 Shell Internationale Research Maatschappij B.V. Soft anticholinergic esters
US7399861B2 (en) 2005-11-10 2008-07-15 Bodor Nicholas S Soft anticholinergic esters
AU2006201878A1 (en) * 2006-03-13 2007-09-27 Foamix Ltd Foamable composition for hyperhidrosis
JP5371235B2 (ja) * 2006-12-06 2013-12-18 ロート製薬株式会社 皮膚外用剤
US10265265B2 (en) * 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
CA2702830C (en) * 2007-10-18 2017-02-28 Stiefel Research Australia Pty Ltd Topical glycopyrrolate formulations
US20100137357A1 (en) * 2008-11-26 2010-06-03 Koleng John J Compositions and methods for hyperhidrosis
US20140037713A1 (en) * 2012-08-03 2014-02-06 Antares Pharma Ipl, Ag Transdermal compositions for anti-cholinergic agents
TR201808040T4 (tr) 2013-03-15 2018-06-21 Bodor Laboratories Inc Hiperhidrozun tedavisine yönelik yumuşak antikolinerjik esterler.
WO2015138700A1 (en) 2014-03-13 2015-09-17 Bodor Laboratories, Inc. Use of selected anticholinergic zwitterions
US20150259283A1 (en) 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030064040A1 (en) * 2001-09-26 2003-04-03 Lukacsko Alison B. Compositions and methods for inhibiting eccrine perspiration in humans

Also Published As

Publication number Publication date
US20170020845A1 (en) 2017-01-26
AU2019257421A1 (en) 2019-11-21
SG11201607480SA (en) 2016-10-28
CN110420167B (zh) 2023-02-17
EP3116498B1 (en) 2018-12-12
US11034652B2 (en) 2021-06-15
KR102586868B1 (ko) 2023-10-11
KR102433868B1 (ko) 2022-08-19
CA2941649C (en) 2021-03-02
US10961191B2 (en) 2021-03-30
JP6756763B2 (ja) 2020-09-16
US10947192B2 (en) 2021-03-16
JP2020079321A (ja) 2020-05-28
AU2015229243A1 (en) 2016-10-20
MX2016011529A (es) 2016-12-07
AU2019257421B2 (en) 2021-10-21
DK3325487T3 (da) 2021-08-02
KR20220119517A (ko) 2022-08-29
CA2941649A1 (en) 2015-09-17
IL247571B (en) 2020-03-31
JP6461267B2 (ja) 2019-01-30
KR20230145522A (ko) 2023-10-17
PH12016501732B1 (en) 2017-02-06
US20200113869A1 (en) 2020-04-16
EP3116498A4 (en) 2017-11-08
US20210078946A1 (en) 2021-03-18
CN110917124B (zh) 2023-06-20
AU2015229243B2 (en) 2019-11-21
JP6293919B2 (ja) 2018-03-14
JP6762047B2 (ja) 2020-09-30
JP2017507970A (ja) 2017-03-23
MY183531A (en) 2021-02-25
CN110917124A (zh) 2020-03-27
CN110420167A (zh) 2019-11-08
PT3325487T (pt) 2021-07-29
US20150320722A1 (en) 2015-11-12
US11084788B2 (en) 2021-08-10
CN106456603A (zh) 2017-02-22
US20210087142A1 (en) 2021-03-25
DK3116498T3 (da) 2019-03-11
IL247571A0 (en) 2016-11-30
BR112016021011A2 (pt) 2017-08-15
BR112016021011A8 (pt) 2021-07-20
KR20160133492A (ko) 2016-11-22
WO2015138776A1 (en) 2015-09-17
BR112016021011B1 (pt) 2022-12-13
US20200093791A1 (en) 2020-03-26
CN106456603B (zh) 2020-01-10
US20210198195A1 (en) 2021-07-01
ZA201607071B (en) 2018-12-19
PL3116498T3 (pl) 2019-05-31
JP2019189650A (ja) 2019-10-31
PT3116498T (pt) 2019-02-11
HUE041868T2 (hu) 2019-05-28
ES2710292T3 (es) 2019-04-24
JP2017214429A (ja) 2017-12-07
PH12016501732A1 (en) 2017-02-06
JP2018115203A (ja) 2018-07-26
EP3116498A1 (en) 2017-01-18
MX369129B (es) 2019-10-30

Similar Documents

Publication Publication Date Title
US11034652B2 (en) Formulation for soft anticholinergic analogs
US11052067B2 (en) Formulation for soft anticholinergic analogs
US11026919B2 (en) Formulation for soft anticholinergic analogs

Legal Events

Date Code Title Description
AS Assignment

Owner name: BRICKELL BIOTECH, INC., FLORIDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ANGULO, DAVID;REEL/FRAME:032953/0140

Effective date: 20140519

Owner name: BRICKELL BIOTECH, INC., FLORIDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KOLENG, JOHN J.;REEL/FRAME:032953/0130

Effective date: 20140310

AS Assignment

Owner name: BODOR LABORATORIES, INC., FLORIDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BRICKELL BIOTECH, INC.;REEL/FRAME:035529/0071

Effective date: 20150417

AS Assignment

Owner name: BODOR LABORATORIES, INC., FLORIDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BODOR, NICHOLAS S;REEL/FRAME:036084/0399

Effective date: 20150501

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: BODOR LABORATORIES, INC., FLORIDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BRICKELL BIOTECH, INC.;REEL/FRAME:040536/0889

Effective date: 20150417